Momelotinib for Myelofibrosis
Momelotinib is FDA-approved at 200 mg orally once daily for adults with intermediate or high-risk myelofibrosis (primary, post-PV, or post-ET) who have anemia, with dose reduction to 150 mg daily in severe hepatic impairment (Child-Pugh C). 1
Indications
Momelotinib is specifically indicated for myelofibrosis patients with anemia, distinguishing it from other JAK inhibitors. The FDA approval encompasses:
- Primary myelofibrosis
- Post-polycythemia vera myelofibrosis
- Post-essential thrombocythemia myelofibrosis
- Risk stratification: Intermediate or high-risk disease
- Key requirement: Presence of anemia 1
The drug functions as a JAK1/JAK2 inhibitor that additionally inhibits ACVR1 (ALK2), leading to hepcidin suppression and improved iron availability for erythropoiesis 1. This dual mechanism addresses both the dysregulated JAK signaling driving myelofibrosis and the anemia that significantly impacts quality of life.
Dosing
Standard dose: 200 mg orally once daily, with or without food 1
Severe hepatic impairment (Child-Pugh C): Reduce starting dose to 150 mg once daily 1. This adjustment is necessary because momelotinib AUC increases by 97% in severe hepatic impairment, though the active metabolite M21 decreases 1.
No dose adjustments required for:
- Mild or moderate hepatic impairment (Child-Pugh A or B)
- Renal impairment (eGFR down to 16.4 mL/min/1.73 m²)
- Age, race, sex, or weight variations 1
Pharmacokinetic considerations: Momelotinib reaches peak concentration at 2 hours post-dose with an elimination half-life of 4-8 hours. The active metabolite M21 has approximately 40% of parent drug activity and circulates at 1.4-2.1 times the parent drug AUC 1.
Contraindications
None listed in FDA labeling 1
However, do not initiate in patients with active infection 1. A 21-day washout from prior JAK inhibitor therapy was required in clinical trials, and grade ≥2 peripheral neuropathy excluded patients from enrollment 2.
Monitoring Recommendations
Before Initiation
- Liver function tests (baseline required) 1
- Complete blood count with differential
- Screen for active infections, including hepatitis B reactivation risk 1
- Exclude grade ≥2 peripheral neuropathy (based on trial exclusion criteria) 2
During Treatment
Hematologic monitoring:
- Monitor for thrombocytopenia and neutropenia; manage with dose reduction or interruption 1
- In clinical trials, grade ≥3 thrombocytopenia occurred in 7% and anemia in 14% of momelotinib-treated patients 3
Hepatic monitoring:
- Periodic liver function tests throughout treatment 1
Infection surveillance:
- Monitor for signs/symptoms of infection, including bacterial infections (occurred in ≥20% of patients) 1
- Watch for hepatitis B reactivation 1
- Grade ≥3 infections occurred in 7% of momelotinib patients in SIMPLIFY-1 4
Peripheral neuropathy assessment:
- Monitor for development of peripheral neuropathy (occurred in 10-11% of patients, predominantly grade 1-2) 4, 3
- Median onset is 32 weeks (227 days) 2
- Critical caveat: Improvement after dose reduction or discontinuation was documented in only 2 of 100 patients in the Mayo Clinic experience, indicating this adverse effect is largely irreversible 2
Cardiovascular monitoring:
- Monitor for major adverse cardiovascular events (MACE); evaluate and treat symptoms promptly 1
- Assess for thrombosis symptoms and treat promptly 1
Malignancy surveillance:
- Monitor for secondary malignancies, particularly in current or past smokers 1
Response Assessment
- Spleen assessment: Bone marrow aspirate and biopsy at diagnosis and as clinically indicated with increased symptoms or signs of progression 5
- Symptom burden: Use MPN-SAF TSS-10 items for standardized assessment 5
- Transfusion requirements: Track transfusion independence and intensity
Key Safety Considerations
Most common adverse reactions (≥20%): thrombocytopenia, hemorrhage, bacterial infection, fatigue, dizziness, diarrhea, nausea 1
Peripheral neuropathy: This is the signature toxicity of momelotinib, occurring in 44% of patients with median onset at 32 weeks. The neuropathy is predominantly sensory, mostly grade 1-2, but shows minimal reversibility even with drug discontinuation 2. This distinguishes momelotinib from other JAK inhibitors and requires careful patient counseling.
Drug interactions:
- OATP1B1/1B3 inhibitors increase momelotinib exposure by 57%; monitor for adverse reactions 1
- BCRP substrates: Momelotinib increases rosuvastatin exposure by 170%; reduce rosuvastatin dose 1
- No clinically significant interactions with strong CYP3A4 inducers/inhibitors or proton pump inhibitors 1
Clinical Context
Momelotinib demonstrated non-inferiority to ruxolitinib for spleen response (26.5% vs 29% achieving ≥35% spleen volume reduction) but failed to meet non-inferiority for symptom response in JAK inhibitor-naïve patients 4. However, momelotinib showed superior transfusion-related outcomes, with improved transfusion independence and reduced transfusion intensity compared to ruxolitinib 4.
In ruxolitinib-experienced patients (SIMPLIFY-2), momelotinib did not demonstrate superiority over best available therapy for spleen reduction (7% vs 6%), though this trial enrolled a heavily pretreated population 3.
The primary clinical niche for momelotinib is myelofibrosis patients with significant anemia, where its unique ACVR1 inhibition provides anemia-related benefits not seen with other JAK inhibitors 6.